3 Custom Synthesis Chemical Stocks With a Strong Future Roadmap: Aarti Industries, Anupam Rasayan India and Tatva Chintan Pharma Chem

Custom synthesis chemical stocks give investors exposure to firms that make specialty intermediates for agro, pharma and material science clients. Results depend on long-term contracts, plant use and raw material costs, which is why customer ties matter as much as headline growth.

This list covers three agro and pharma intermediate stocks: Aarti Industries for benzene-based specialty chemicals and intermediates, Anupam Rasayan India for custom synthesis of specialty chemicals for global agro, pharma and material science clients and Tatva Chintan Pharma Chem for phase transfer catalysts and specialty chemicals. Every figure comes from the latest reported financials and the 7 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Custom Synthesis Chemical Stocks?

Custom synthesis chemical stocks are shares of companies that make specialty intermediates and catalysts to the specifications of global customers. Results depend on contract wins, plant use, raw material costs and operating margin, so long-term contracts and a steady pipeline separate the stronger names.

Custom Synthesis Chemical Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three custom synthesis chemical stocks as of the 7 October 2026 close.

Among agro and pharma intermediate stocks, Aarti Industries trades below the industry P/E, while Anupam Rasayan and Tatva Chintan trade at a premium to the industry multiple.

Why Do Custom Synthesis Chemical Stocks Have a Strong Roadmap in India?

Custom synthesis chemical stocks have a strong roadmap in India because global firms are diversifying chemical supply, Indian makers are adding capacity and long-term contracts give visibility. Three drivers stand out.

• Supply diversification: Global firms add Indian chemical makers to cut risk.
• Capacity additions: New plants widen the product range.
• Long-term contracts: Multi-year deals support revenue visibility.

Aarti Industries: Benzene-Based Specialty Chemicals Anchor the Roadmap

Aarti Industries' roadmap rests on benzene-based specialty chemicals and intermediates, with new capacity and long-term contracts supporting revenue.

Revenue grew from Rs 6,086.28 crore in FY22 to Rs 8,290.97 crore in FY26, a 36.2% rise, and FY26 revenue was 13.8% higher than FY25. FY26 net profit rose 26.7% to Rs 419.18 crore. In Q1 FY27, revenue grew 40.6% to Rs 2,630.00 crore, and net profit rose 260.5% to Rs 155.00 crore. Operating margin was 13.07% in FY26 and 14.73% in Q1 FY27 against 11.57% a year earlier.

Debt to equity is 0.83 and return on equity is 7.04%. FY26 operating cash flow was Rs 780.80 crore against capital expenditure of Rs 1,124.28 crore. Aarti Industries paid a dividend of Rs 1 per share for FY26, a yield of 0.20%. At a P/E of 33.51 against an industry P/E of 36.85, the stock trades below its industry multiple.

What to watch: FY26 capex of Rs 1,124.28 Cr was above operating cash flow of Rs 780.80 Cr, and FY25 net profit of Rs 330.92 Cr was lower than the Rs 416.47 Cr of FY24. Debt to equity of 0.83 deserves tracking.

Anupam Rasayan India: Custom Synthesis for Global Clients Drives the Pipeline

Anupam Rasayan's roadmap rests on custom synthesis of specialty chemicals for global agro, pharma and material science clients, with long-term contracts supporting growth.

Revenue grew from Rs 1,081.11 crore in FY22 to Rs 2,383.63 crore in FY26, a 120.5% rise, and FY26 revenue was 64.6% higher than FY25. FY26 net profit rose 38.9% to Rs 222.20 crore. Over four years, net profit rose from Rs 152.18 crore in FY22 to Rs 222.20 crore. In Q1 FY27, revenue grew 36.0% to Rs 667.55 crore, and net profit rose 5.7% to Rs 51.22 crore. Operating margin was 22.96% in FY26 and 26.71% in Q1 FY27 against 26.59% a year earlier.

Debt to equity is 0.56 and return on equity is 5.10%. FY26 operating cash flow was Rs 334.33 crore against capital expenditure of Rs 555.16 crore. Anupam Rasayan paid a dividend of Rs 1.5 per share for FY26, a yield of 0.13%. At a P/E of 59.02 against an industry P/E of 36.85, the stock trades above its industry multiple.

What to watch: FY26 capex of Rs 555.16 Cr was above operating cash flow of Rs 334.33 Cr, and Q1 FY27 net profit growth of 5.7% is well below the 38.9% of FY26. The P/E of 59.02 sits above the industry P/E of 36.85, so earnings delivery matters for the valuation.

Tatva Chintan Pharma Chem: Phase Transfer Catalysts and New Products Build the Next Leg

Tatva Chintan's roadmap rests on phase transfer catalysts and specialty chemicals, with new products and export customers supporting revenue.

Revenue grew from Rs 442.54 crore in FY22 to Rs 509.41 crore in FY26, a 15.1% rise, and FY26 revenue was 32.3% higher than FY25. FY26 net profit rose from Rs 5.71 crore to Rs 42.05 crore. In Q1 FY27, revenue grew 43.9% to Rs 169.84 crore, and net profit rose 140.3% to Rs 15.98 crore. Operating margin was 19.18% in FY26 and 20.21% in Q1 FY27 against 15.82% a year earlier.

Debt to equity is 0.15 and return on equity is 5.38%. FY26 operating cash flow was Rs 31.49 crore against capital expenditure of Rs 113.77 crore. Tatva Chintan paid a dividend of Rs 2 per share for FY26, a yield of 0.10%. At a P/E of 90.78 against an industry P/E of 36.85, the stock trades above its industry multiple.

What to watch: FY26 capex of Rs 113.77 Cr was above operating cash flow of Rs 31.49 Cr, and return on equity of 5.38% is modest. The P/E of 90.78 sits above the industry P/E of 36.85, so earnings delivery matters for the valuation.

Best Custom Synthesis Chemical Stocks in India: Aarti Industries vs Anupam Rasayan vs Tatva Chintan on Key Financials

Among the best custom synthesis chemical stocks in India, Anupam Rasayan leads on FY26 operating margin and five-year revenue growth; Tatva Chintan leads on Q1 FY27 revenue growth; Aarti Industries leads on return on equity and the lowest P/E. The table puts the numbers side by side.

Specialty chemical earnings follow contract wins and raw material costs, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Specialty Intermediate Chemical Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen custom synthesis chemical stocks and shortlist specialty intermediate chemical stocks to buy.

1. Compare each stock's P/E with its industry P/E, which is 36.85 for all three here.
2. Track operating margin across several quarters, because input costs can move faster than prices.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these custom synthesis chemical stocks

Risks to Consider Before Investing in Custom Synthesis Chemical Stocks

• Valuation: Anupam Rasayan and Tatva Chintan trade at 59.02 and 90.78 times earnings against an industry multiple of 36.85.
• Low returns: Return on equity is 7.04% at Aarti, 5.10% at Anupam and 5.38% at Tatva.
• Capex: Aarti's FY26 capex of Rs 1,124.28 Cr was above its operating cash flow of Rs 780.80 Cr.
• Profit swings: Aarti's net profit was Rs 1,185.90 Cr in FY22 and Rs 419.18 Cr in FY26.

Download the Univest iOS App or Univest Android App to track Aarti Industries, Anupam Rasayan and Tatva Chintan live.

Final Take: Which Stock Has the Strongest Roadmap?

These three specialty intermediate chemical stocks cover benzene-based specialty chemicals, custom synthesis, and phase transfer catalysts. Anupam Rasayan leads on FY26 operating margin and five-year revenue growth; Tatva Chintan leads on Q1 FY27 revenue growth; Aarti Industries leads on return on equity and the lowest P/E.

Across agro and pharma intermediate stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the specialty intermediate chemical stocks to buy discussed here.

FAQs on Custom Synthesis Chemical Stocks

Which are the best custom synthesis chemical stocks in India with a strong roadmap?

Ans. Aarti Industries, Anupam Rasayan India and Tatva Chintan Pharma Chem stand out for their roadmaps in specialty intermediates and custom-made chemicals. FY26 revenue growth was 13.8% at Aarti Industries, 64.6% at Anupam Rasayan and 32.3% at Tatva Chintan, and return on equity ranges from 5.10% to 7.04%.

Is Aarti Industries a good stock to buy now?

Ans. Aarti Industries has a debt to equity ratio of 0.83, a return on equity of 7.04% and a P/E of 33.51 against an industry P/E of 36.85. Valuation, low returns and capex move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Aarti Industries, Anupam Rasayan and Tatva Chintan?

Ans. The P/E ratio is 33.51 for Aarti Industries (industry 36.85), 59.02 for Anupam Rasayan (industry 36.85) and 90.78 for Tatva Chintan (industry 36.85). Only Anupam Rasayan and Tatva Chintan trade at or above the industry multiple.

Which of these custom synthesis chemical stocks has the highest return on equity?

Ans. Aarti Industries has the highest return on equity at 7.04%, followed by Tatva Chintan Pharma Chem at 5.38% and Anupam Rasayan India at 5.10%.

What are the risks of investing in custom synthesis chemical stocks?

Ans. The main risks are high valuations, low returns on equity, capex ahead of cash flow and uneven profit history. Anupam Rasayan and Tatva Chintan trade at 59.02 and 90.78 times earnings against an industry multiple of 36.85.

How did Aarti Industries, Anupam Rasayan and Tatva Chintan perform in Q1 FY27?

Ans. Aarti Industries reported revenue of Rs 2,630.00 crore, up 40.6% year on year, and net profit rose 260.5% to Rs 155.00 crore. Anupam Rasayan India reported revenue of Rs 667.55 crore, up 36.0% year on year, and net profit rose 5.7% to Rs 51.22 crore. Tatva Chintan Pharma Chem reported revenue of Rs 169.84 crore, up 43.9% year on year, and net profit rose 140.3% to Rs 15.98 crore.

Do custom synthesis chemical stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.20% for Aarti Industries, 0.13% for Anupam Rasayan and 0.10% for Tatva Chintan, based on dividends declared for FY26.

How can I invest in custom synthesis chemical stocks in India?

Ans. You can buy custom synthesis chemical stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.